Abstract
Therapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies.
Keywords: Therapeutic antibodies, hybridoma, fusion partner, B cells, EBV transformation, miR transformation.
Current Pharmaceutical Design
Title:Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique
Volume: 22 Issue: 7
Author(s): Xenia A. Glukhova, Olga V. Prusakova, Julia A. Trizna, Michael M. Zaripov, Gaida V. Afanas’eva, Anatoly S. Glukhov, Rimma A. Poltavtseva, Alexei A. Ivanov, Marco Avila-Rodriguez, George E. Barreto, Gjumrakch Aliev and Igor P. Beletsky
Affiliation:
Keywords: Therapeutic antibodies, hybridoma, fusion partner, B cells, EBV transformation, miR transformation.
Abstract: Therapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies.
Export Options
About this article
Cite this article as:
Glukhova A. Xenia, Prusakova V. Olga, Trizna A. Julia, Zaripov M. Michael, Afanas’eva V. Gaida, Glukhov S. Anatoly, Poltavtseva A. Rimma, Ivanov A. Alexei, Avila-Rodriguez Marco, Barreto E. George, Aliev Gjumrakch and Beletsky P. Igor, Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique, Current Pharmaceutical Design 2016; 22 (7) . https://dx.doi.org/10.2174/1381612822666151223102845
DOI https://dx.doi.org/10.2174/1381612822666151223102845 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Editorial [Hot Topic: The Chemistry and Biology of Small Molecules Acting on Nucleic Acids (Guest Editors: P.B. Arimondo, T. Garestier, J.-L. Mergny Dedicated to the Memory of Professor Claude Helene)]
Current Medicinal Chemistry - Anti-Cancer Agents Paullones as Inhibitors of Protein Kinases
Current Topics in Medicinal Chemistry Targeting the Wingless Signaling Pathway with Natural Compounds as Chemopreventive or Chemotherapeutic Agents
Current Pharmaceutical Biotechnology Hypomethylation and Activation of Syncytin-1 Gene in Endometriotic Tissue
Current Pharmaceutical Design Sympathetic Signaling in Angiogenesis: Implications for Cancer Progression
Current Cancer Therapy Reviews Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives
Current Cancer Therapy Reviews Molecular Mechanisms of Drug Photodegradation and Photosensitization
Current Pharmaceutical Design Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy
Current Pharmaceutical Design Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets Detection of VEGF165 Using an Aptamer Affinity Probe in Microchip Capillary Electrophoresis
Current Pharmaceutical Analysis A Review of Recent Patents Concerning Therapy of Respiratory Diseases Using Gene Silencing by RNAi (RISC) and EGS (RNAse P)
Recent Patents on Inflammation & Allergy Drug Discovery Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets MMPs in Ovarian Cancer as Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Current Topics in Medicinal Chemistry